- Home
- RXRX
as 02-21-2025 4:00pm EST
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. It is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Upcoming Earnings Alert:
Get ready for potential market movements as Recursion Pharmaceuticals Inc. RXRX prepares to release earnings report on 28 Feb 2025.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | SALT LAKE CITY |
| Market Cap: | 2.6B | IPO Year: | 2021 |
| Target Price: | $8.75 | AVG Volume (30 days): | 32.2M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.60 - $15.74 | Next Earning Date: | 02-28-2025 |
| Revenue: | $65,184,000 | Revenue Growth: | 37.64% |
| Revenue Growth (this year): | 61.89% | Revenue Growth (next year): | 30.83% |
Stock Insider Trading Activity of Recursion Pharmaceuticals Inc. (RXRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gibson Christopher | RXRX | Chief Executive Officer | Feb 5 '25 | Sell | $7.90 | 40,000 | $316,000.00 | 1,273,156 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Jan 8 '25 | Sell | $7.18 | 40,000 | $287,200.00 | 1,273,156 | |
| Gibson Christopher | RXRX | Chief Executive Officer | Dec 4 '24 | Sell | $7.14 | 40,000 | $285,600.00 | 1,273,156 |
Latest Recursion Pharmaceuticals Inc. News
RXRX Breaking Stock News: Dive into RXRX Ticker-Specific Updates for Smart Investing
Insider Monkey
a day ago
Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)
Insider Monkey
3 days ago
Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025
GlobeNewswire
3 days ago
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
BioPharma Dive
3 days ago
Recursion CEO launches pre-seed fund in response to NIH cuts
Investor's Business Daily
4 days ago
Recursion Pharmaceuticals Stock Scores RS Ratings Over 90
Insider Monkey
4 days ago
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)
GlobeNewswire
4 days ago
Altitude Lab Startups Raise $154M in Capital
Zacks
4 days ago
Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock
Compare RXRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RXRX Recursion Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.